Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III randomized double-blind study of NE-58095NF versus NE-58095 2.5 mg in involutional osteoporosis
jRCT2080222389Phase 3
- Sponsor
- Ajinomoto
- Start
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of risedronate in involutional osteoporosis (2 arms), sponsored by Ajinomoto.
02
Drugs
risedronate
03
Conditions
involutional osteoporosis
Beyond the preview
Go deeper on jRCT2080222389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222389.